Attached files
file | filename |
---|---|
EX-10 - MABVAX THERAPEUTICS HOLDINGS, INC. | ex10-04072016_010448.htm |
(Exact name of registrant as specified in its charter.)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
On April 1, 2016 MabVax Therapeutics Holdings, Inc. ("Company") entered into a consulting agreement ("Agreement") with Jeffrey V. Ravetch, M.D., Ph.D., a member of the Company's Board of Directors and the Theresa and Eugene Lang Professor at the Rockefeller University and Head of its Leonard Wagner Laboratory of Molecular Genetics and Immunology. Dr. Ravetch, in addition to his services as a Board member, is providing key technology and product development, as well as corporate development, consulting services to the Company under the Agreement.
The term of the agreement is 2 years beginning January 1, 2016, and Dr. Ravetch will receive $100,000 cash compensation for each year of the Agreement.
The foregoing description of the material terms of the Agreement is subject to, and qualified in its entirety by the text of the Consulting Agreement filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
Exhibit No. Description
10.1 Consulting Agreement between the Company and Jeffrey V. Ravetch, dated as of January 1, 2016
MabVax Therapeutics Holdings, Inc. |
By: | /s/ Gregory P. Hanson |
Name: Gregory P. Hanson | |
Title: Chief Financial Officer |
Exhibit No.
|
Description
|
|
EX-10.1
|
Consulting Agreement between the Company and Jeffrey V. Ravetch, dated as of January 1, 2016
|